Granted Patent
B2
US 12,540,188 · App. 18/017,838 · Granted Feb 3, 2026
IL10Rα/IL2Rγ synthetic cytokines
Inventors:
Robert Kastelein (Menlo Park, CA); Deepti Rokkam (Menlo Park, CA); Patrick J. Lupardus (Menlo Park, CA); Mahalakshmi Ramadass (Menlo Park, CA); Sandro Vivona (Menlo Park, CA)
Assignee:
SYNTHEKINE, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are IL10Rα/IL2Rγ binding molecules that bind to IL10Rα and IL2Rγ and comprise an anti-IL2Rγ sdAb and an anti-IL2Rγ V H H antibody.
Claims (17)
1 . An IL10Rα/IL2Rγ binding molecule that specifically binds to IL10Rα subunit (IL10Rα) and IL2Rγ subunit (IL2Rγ),
wherein the binding molecule comprises a single-domain antibody (sdAb) that specifically binds to IL10Rα (an anti-IL10Rα sdAb), wherein the anti-IL10Rα sdAb comprises a CDR1 comprising SEQ ID NO: 38, a CDR2 comprising a SEQ ID NO: 56 and a CDR 3 comprising SEQ ID NO: 74 and a sdAb that specifically binds to IL2Rγ (an anti-IL2Rγ sdAb) comprising a CDR1 comprising SEQ ID NO: 97, a CDR2 comprising a SEQ ID NO: 120 and a CDR3 comprising SEQ ID NO: 143,
wherein the IL10Rα sdAb and IL2Rγ sdAb are in stable association via a peptide bond, a peptide linker, or complementary knob and hole Fc domains.
2 . The IL10Rα/IL2Rγ binding molecule of claim 1 , wherein the anti-IL10Rα sdAb is a VHH antibody and/or the anti-IL2Rγ sdAb is a VHH antibody.
3 . The IL10Rα/IL2Rγ binding molecule of claim 1 , wherein the anti-IL10Rα sdAb and the anti-IL2Rγ sdAb are joined by a peptide linker.
4 . The IL10Rα/IL2Rγ binding molecule of claim 3 , wherein the peptide linker comprises between 1 and 50 amino acids.
5 . The IL10Rα/IL2Rγ binding molecule of claim 4 , wherein the peptide linker comprises a sequence of GGGS (SEQ ID NO: 9).
6 . The IL10Rα/IL2Rγ binding molecule of claim 1 , wherein the binding molecule comprises the anti-IL10Rα sdAb linked to the N-terminus of a linker and the anti-IL2Rγ sdAb linked to the C-terminus of the linker.
7 . The IL10Rα/IL2Rγ binding molecule of claim 6 , wherein the anti-IL10Rα sdAb comprises a sequence having at least 90% sequence identity to SEQ ID NO: 206.
8 . The IL10Rα/IL2Rγ binding molecule of claim 6 , wherein the anti-IL10Rα sdAb comprises SEQ ID NO: 206 or SEQ ID NO: 203.
9 . The IL10Rα/IL2Rγ binding molecule of claim 6 , wherein the anti-IL2Rγ sdAb comprises a sequence having at least 90% sequence identity to SEQ ID NO: 229.
10 . The IL10Rα/IL2Rγ binding molecule of claim 6 , wherein the anti-IL2Rγ sdAb comprises SEQ ID NO: 229, SEQ ID NO: 213 or SEQ ID NO: 217.
11 . The IL10Rα/IL2Rγ binding molecule of claim 6 , wherein the IL10Rα sdAb comprises a sequence having at least 90% sequence identity to SEQ ID NO: 206, and the anti-IL2Rγ sdAb comprises a sequence having at least 90% sequence identity to SEQ ID NO: 229.
12 . The IL10Rα/IL2Rγ binding molecule of claim 6 ,
wherein the anti-IL10Rα sdAb comprises SEQ ID NO: 206 or SEQ ID NO: 203, and the anti-IL2Rγ sdAb comprises SEQ ID NO: 229, SEQ ID NO: 213 or SEQ ID NO: 217.
13 . The IL10Rα/IL2Rγ binding molecule of claim 1 , wherein the binding molecule comprises the anti-IL2Rγ sdAb linked to the N-terminus of a linker and the anti-IL10Rα sdAb linked to the C-terminus of the linker.
14 . A pharmaceutical composition comprising the IL10Rα/IL2Rγ binding molecule of claim 1 and a pharmaceutically acceptable carrier.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 11, 2023
From: KASTELEIN, ROBERT; ROKKAM, DEEPTI; LUPARDUS, PATRICK J.; RAMDASS, MAHALAKSHMI; VIVONA, SANDRO
To: INC., SYNTHEKINE
Reel/Frame 062954/0136 →
Continuity (5)
Provisional Application
63135884
· Jan 11, 2021
Provisional Application
63136098
· Jan 11, 2021
Provisional Application
63078745
· Sep 15, 2020
Provisional Application
63061562
· Aug 5, 2020
References Cited (187)
US 7553932B1
· Von Herrath et al.
· 2009
[cited by applicant]
US 8258268B2
· Wu et al.
· 2012
[cited by applicant]
US 8420784B2
· Kato et al.
· 2013
[cited by applicant]
US 8921528B2
· Holt et al.
· 2014
[cited by applicant]
US 8975382B2
· Revets et al.
· 2015
[cited by applicant]
US 9028830B2
· Tso et al.
· 2015
[cited by applicant]
US 9334331B2
· Igawa et al.
· 2016
[cited by applicant]
US 20060002935A1
· Brewis et al.
· 2006
[cited by applicant]
US 20060024295A1
· Brunetta
· 2006
[cited by applicant]
US 20090155275A1
· Wu et al.
· 2009
[cited by applicant]
US 20100233173A1
· Wu
· 2010
[cited by applicant]
US 20100297127A1
· Ghilardi et al.
· 2010
[cited by applicant]
US 20110028695A1
· Revets et al.
· 2011
[cited by applicant]
US 20110053865A1
· Saunders et al.
· 2011
[cited by applicant]
US 20110142831A1
· Cua et al.
· 2011
[cited by applicant]
US 20120201746A1
· Liu et al.
· 2012
[cited by applicant]
US 20120225081A1
· Gschwind et al.
· 2012
[cited by applicant]
US 20120316324A1
· Adams et al.
· 2012
[cited by applicant]
US 20130189262A1
· Wong et al.
· 2013
[cited by applicant]
US 20140065142A1
· Roschke et al.
· 2014
[cited by applicant]
US 20140154256A1
· Wu et al.
· 2014
[cited by applicant]
US 20140170154A1
· Presta
· 2014
[cited by applicant]
US 20160046730A1
· Ghayur et al.
· 2016
[cited by applicant]
US 20160251440A1
· Roobrouck et al.
· 2016
[cited by applicant]
US 20200157237A1
· Regev et al.
· 2020
[cited by applicant]
US 20210260162A1
· Gonzalez et al.
· 2021
[cited by applicant]
US 20230272094A1
· Kastelein et al.
· 2023
[cited by applicant]
US 20240181009A1
· Gonzalez et al.
· 2024
[cited by applicant]
US 20250163162A1
· Kastelein et al.
· 2025
[cited by applicant]
CN 101952312A
· 2011
[cited by applicant]
CN 103396482A
· 2013
[cited by applicant]
CN 104011221A
· 2014
[cited by applicant]
CN 104619334A
· 2015
[cited by applicant]
CN 111018985A
· 2020
[cited by applicant]
CN 111040035A
· 2020
[cited by applicant]
EP 2213735A1
· 2010
[cited by applicant]
JP 07223968A
· 1995
[cited by applicant]
JP 2004505641A
· 2004
[cited by applicant]
JP 2006504401A
· 2006
[cited by applicant]
JP 2011502163A
· 2011
[cited by applicant]
WO 2002012345A2
· 2002
[cited by applicant]
WO 2003089603A2
· 2003
[cited by applicant]
WO 2006036878A2
· 2006
[cited by applicant]
WO 2008011081A2
· 2008
[cited by applicant]
WO 2009058888A1
· 2009
[cited by applicant]
WO 2009068631A1
· 2009
[cited by applicant]
WO 2010142551A2
· 2010
[cited by applicant]
WO 2011051327A2
· 2011
[cited by applicant]
WO 2011095604A1
· 2011
[cited by applicant]
WO 2013006544A1
· 2013
[cited by applicant]
WO 2013059299A1
· 2013
[cited by applicant]
WO 2015044386A1
· 2015
[cited by applicant]
WO 2015142675A2
· 2015
[cited by applicant]
WO 2016097313A1
· 2016
[cited by applicant]
WO 2017198212A1
· 2017
[cited by applicant]
WO 2018182935A1
· 2018
[cited by applicant]
WO 2018233624A1
· 2018
[cited by applicant]
WO 2019129221A1
· 2019
[cited by applicant]
WO 20200052543A1
· 2020
[cited by applicant]
WO 2020094834A1
· 2020
[cited by applicant]
WO 2020094836A1
· 2020
[cited by applicant]
WO 2020113164A1
· 2020
[cited by applicant]
WO 2020135559A1
· 2020
[cited by applicant]
WO 2020144164A1
· 2020
[cited by applicant]
WO 2020187711A1
· 2020
[cited by applicant]
WO 2022032006A2
· 2022
[cited by applicant]
WO 2022032040A1
· 2022
[cited by applicant]
WO 2022032045A1
· 2022
[cited by applicant]
WO WO2022031884
· 2022
[cited by examiner]
WO WO2022031885
· 2022
[cited by examiner]
WO WO2022032022
· 2022
[cited by examiner]
WO WO2022055641
· 2022
[cited by examiner]
WO 2022150791A2
· 2022
[cited by applicant]
WO WO2022150788
· 2022
[cited by examiner]
International Search Report in PCT/US2021/044858, mailed Dec. 20, 2021, (three pages).
[cited by applicant]
Delgoffe et al., “Interpreting mixed signals: the cell's cytokine conundrum,” Current Opinion in Immunology, vol. 23(5), pp. 632-638, Retrieved from the internet, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC319002…
[cited by applicant]
Almagro et al., “Humanization of Antibodies”, Frontiers in Bioscience, vol. 13, No. 5, Jan. 1, 2008, pp. 1619-1633.
[cited by applicant]
Apantaku , “Breast Cancer Diagnosis and Screening”, American Family Physician, vol. 62, No. 3, Aug. 1, 2000, pp. 596-602.
[cited by applicant]
Crepaldi et al., “Up-Regulation of IL-10R1 Expression is Required to Render Human Neutrophils Fully Responsive to IL-10”, The Journal of Immunology, vol. 167, No. 4, Aug. 15, 2001, pp. 2312-2322.
[cited by applicant]
De Genst et al., “Antibody Repertoire Development in Camelids”, Developmental and Comparative Immunology, vol. 30, Nos. 1-2, 2006, pp. 187-198.
[cited by applicant]
Donnelly et al., “The Expanded Family of Class II Cytokines that Share the IL-10 Receptor-2 (IL-10R2) Chain”, Journal of Leukocyte Biology, vol. 76, No. 2, Aug. 2004, pp. 314-321.
[cited by applicant]
Fenton et al., “Rheostat Positions: A New Classification of Protein Positions Relevant to Pharmacogenomics”, Medicinal Chemistry Research, vol. 29, Jun. 7, 2020, pp. 1133-1146.
[cited by applicant]
Fu et al., “Camelus Bactrianus Clone VHH-BC-17 Immunoglobulin Heavy Chain Variable Region mRNA, Rartial Cds”, Genbank Entry (online) National Center for Biotechnology Information, Available online at: www.ncbi.nlm.nih.g…
[cited by applicant]
Fu et al., “Comparison of Camelus Bactrianus VHH Sequences from Conventional and Heavy Chain Antibodies”, National Center for Biotechnology Information, Available Online at: https://www.ncbi.nlm.nih.gov/nucleotide/KF179…
[cited by applicant]
Jiang et al., “Regulation of Interleukin-10 Receptor Ubiquitination and Stability by Beta-TrCP-Containing Ubiquitin E3 Ligase”, PLoS ONE, vol. 6, No. 11, Nov. 8, 2011, pp. 1-14.
[cited by applicant]
Khan et al., “Adjustable Locks and Flexible Keys: Plasticity of Epitope-Paratope Interactions in Germline Antibodies”, The Journal of Immunology, vol. 192, Issue 11, 2014, pp. 5398-5405.
[cited by applicant]
Lundin et al., “Production and Partial Characterization of Mouse Monoclonal Antibodies Recognizing Common Cytokine Receptor Gamma Chain (γc) of Human, Mouse and Primate Origin”, Acta Pathologica, Microbiologica, et Immu…
[cited by applicant]
Martin et al., “Genetic and Hormonal Risk Factors in Breast Cancer”, Journal of the National Cancer Institute, vol. 92, No. 14, Jul. 19, 2000, pp. 1126-1135.
[cited by applicant]
Application No. PCT/US2021/044602 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 10 pages.
[cited by applicant]
Application No. PCT/US2021/044602 , International Search Report and Written Opinion, Mailed On Feb. 2, 2022, 13 pages.
[cited by applicant]
Application No. PCT/US2021/044603 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 9 pages.
[cited by applicant]
Application No. PCT/US2021/044803 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 7 pages.
[cited by applicant]
Application No. PCT/US2021/044803 , International Search Report and Written Opinion, Mailed On Jan. 26, 2022, 11 pages.
[cited by applicant]
Application No. PCT/US2021/044834 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 11 pages.
[cited by applicant]
Application No. PCT/US2021/044834 , International Search Report and Written Opinion, Mailed On Feb. 2, 2022, 15 pages.
[cited by applicant]
Application No. PCT/US2021/044853 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 7 pages.
[cited by applicant]
Application No. PCT/US2021/044853 , International Search Report and Written Opinion, Mailed On Dec. 17, 2021, 10 pages.
[cited by applicant]
Application No. PCT/US2021/044858 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 7 pages.
[cited by applicant]
Application No. PCT/US2022/012049 , International Preliminary Report on Patentability, Mailed On Jul. 20, 2023, 10 pages.
[cited by applicant]
Application No. PCT/US2022/012049 , International Search Report and Written Opinion, Mailed On Jun. 21, 2022, 14 pages.
[cited by applicant]
Application No. PCT/US2022/012055 , International Preliminary Report on Patentability, Mailed On Jul. 20, 2023, 12 pages.
[cited by applicant]
Application No. PCT/US2022/012055 , International Search Report and the Written Opinion, Mailed On Jun. 29, 2022, 18 pages.
[cited by applicant]
Pingwara et al., “IFN-λ Modulates the Migratory Capacity of Canine Mammary Tumor Cells via Regulation of the Expression of Matrix Metalloproteinases and Their Inhibitors”, Cells, vol. 10, No. 5, Apr. 23, 2021, pp. 1-15.
[cited by applicant]
Shouval et al., “Interleukin 10 Receptor Signaling: Master Regulator of Intestinal Mucosal Homeostasis in Mice and Humans”, Advances in Immunology, vol. 122, 2014, pp. 1-29.
[cited by applicant]
Yoshinaga et al., “Ig L-Chain Shuffling for Affinity Maturation of Phage Library-Derived Human Anti-Human MCP-1 Antibody Blocking its Chemotactic Activity”, The Journal of Biochemistry, vol. 143, No. 5, May 2008, pp. 59…
[cited by applicant]
U.S. Appl. No. 18/260,709, filed Jan. 11, 2022, Synthekine, Inc.
[cited by applicant]
Franke et al. “Human and Murine Interleukin 23 Receptors are Novel Substrates for a Disintegrin and Metalloproteases ADAM10 and ADAM17”, The Journal of Biological Chemistry, vol. 291, No. 20, May 13, 2016, pp. 10551-105…
[cited by applicant]
Application No. PCT/US2021/044603 , International Search Report and Written Opinion, Mailed On Feb. 2, 2022, 12 pages.
[cited by applicant]
Watzka et al., “Guided Selection of Antibody Fragments Specific for Human Interferon Gamma Receptor 1 from a Human VH- and VL-Gene Repertoire”, Immunotechnology, vol. 3, No. 4, Jan. 1998, pp. 279-291.
[cited by applicant]
Weidle et al., “The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer”, Cancer Genomics & Proteomics, vol. 10, No. 1, Jan.-Feb. 2013, pp. 1-18.
[cited by applicant]
Wilton et al., “sdAb-DB: The Single Domain Antibody Database”, American Chemical Society Synthetic Biology, vol. 7, No. 11, Nov. 16, 2018, pp. 2480-2484.
[cited by applicant]
EP21853105.1 , “Partial Supplementary European Search Report”, dated Apr. 4, 2025, 16 pages.
[cited by applicant]
EP21853257.0 , Extended European Search Report, dated Mar. 28, 2025, 7 pages.
[cited by applicant]
EP21853681.1 , “Partial Supplementary European Search Report”, dated Apr. 2, 2025, 14 pages.
[cited by applicant]
EP21854022.7 , “Partial Supplementary European Search Report”, dated Aug. 21, 2024, 13 pages.
[cited by applicant]
Gorby et al., “Engineered IL-10 Variants Elicit Potent Immuno-Modulatory Activities at Therapeutic Low Ligand Doses”, Science Signaling, vol. 13, No. 649, Sep. 15, 2020, pp. 1-46.
[cited by applicant]
Harris et al., “A Bispecific Antibody Agonist of the II-2 Heterodimeric Receptor Preferentially Promotes in Vivo Expansion of CD8 and NK Cells”, Scientific Reports, vol. 11, No. 1, May 19, 2021, 15 pages.
[cited by applicant]
Hechinger et al., “Therapeutic Activity of Multiple Common γ-Chain Cytokine Inhibition in Acute and Chronic GVHD”, Blood, vol. 125, No. 3, Jan. 15, 2015, pp. 570-580.
[cited by applicant]
Le Floc'h et al., “Blockade of Common Gamma Chain Cytokines with REGN7257, An Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, Protected Mice from Graft-Versus-Host Disease”, Transplantation and Cellular Therap…
[cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” PNAS, 79(6), Mar. 1, 1982, pp. 1979-1983.
[cited by applicant]
Victoria et al., “Activation of Toll-Like Receptor 2 Increases Macrophage Resistance to HIV-1 Infection”, Immunobiology, vol. 218, No. 12, Dec. 2013, pp. 1529-1536.
[cited by applicant]
Winkler et al., “Changing The Antigen Binding Specificity By Single Point Mutations of An Anti-p24 (HIV-1) Antibody”, The Journal of Immunology, vol. 165, No. 8, Oct. 15, 2000, pp. 4505-4514.
[cited by applicant]
Zadka et al., “The Expression of IL10RA in Colorectal Cancer and its Correlation with the Proliferation Index and the Clinical Stage of the Disease”, Cytokine, vol. 110, Oct. 2018, pp. 116-125.
[cited by applicant]
U.S. Appl. No. 19/180,030, filed Apr. 15, 2025, Kastelein et al.
[cited by applicant]
Aagaard et al., “RNAi Therapeutics: Principles, Prospects and Challenges”, Advanced Drug Delivery Reviews, vol. 59, Issues 2-3, Mar. 30, 2007, pp. 75-86.
[cited by applicant]
Bork, Genome Research, vol. 10, 2000, pp. 398-400.
[cited by applicant]
Brown et al., J Immunol., 156(9), May 1996, pp. 3285-3291.
[cited by applicant]
Burgess et al., J. Cell Biol., vol. 111, 1990, pp. 2129-2138.
[cited by applicant]
Clark et al., “Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases”, Journal of Medicinal Chemistry, vol. 57, No. 12, Jan. 13, 2014, pp. 5023-5038.
[cited by applicant]
Difalco et al., “The Improved Survival of Hematopoietic Cells Cultured with a Fusion Protein of Insulin-Like Growth Factor II (IGF-II) and Interleukin 3 (IL-3) is Associated with Increases in Bcl-XI and Phosphatidylinos…
[cited by applicant]
Duarte et al., “La Vía JAK-STAT De Señalización Intracelular Y Su Repercusión En Oncogénesis, Inmunomodulación Y Desarrollo”, Medicina Clínica (Barc), vol. 114, 2000, pp. 227-234.
[cited by applicant]
Edwards et al., Mol. Biol., vol. 334(1), Nov. 14, 2003, pp. 103-118.
[cited by applicant]
Application No. EP18774902.3, Extended European Search Report, dated Nov. 26, 2020, 11 pages.
[cited by applicant]
Application No. EP18774902.3 , Office Action, Mailed On Nov. 28, 2023, 4 pages.
[cited by applicant]
Gillies et al., “Bi-Functional Cytokine Fusion Proteins for Gene Therapy and Antibody-Targeted Treatment of Cancer”, Cancer Immunology, Immunotherapy, vol. 51, No. 8, Oct. 2002, pp. 449-460.
[cited by applicant]
Goel et al., J. Immunol., vol. 173(2), Dec. 15, 2004, pp. 7358-7367.
[cited by applicant]
Gorby et al., “Mapping Determinants of Cytokine Signaling via Protein Engineering”, Frontiers in Immunology, vol. 9, Article 2143, Sep. 2018, pp. 1-9.
[cited by applicant]
Guido et al., “Virtual Screening and Its Integration With Modern Drug Design Technologies”, Current Medicinal Chemistry, vol. 15, No. 1, Feb. 2008, pp. 37-46.
[cited by applicant]
Jahn et al., “An II12-II2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack”, PLoS ONE, vol. 7, No. 9, Sep. 18, 2012, pp. 1-13.
[cited by applicant]
Kawahara et al., “Replacing Factor-dependency With That For Lysozyme: Affordable Culture of II-6-dependent Hybridoma by Transfecting Artificial Cell Surface Receptor”, Biotechnology and Bioengineering, vol. 74, No. 5, S…
[cited by applicant]
Kermer et al., “Combining Antibody-Directed Presentation of IL-15 and 4-1 BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy”, Molecular Cancer Therapeutics, vol. 13, No. 1, Jan. 2014, pp. 112-121.
[cited by applicant]
Kontermann, “Dual Targeting Strategies with Bispecific Antibodies”, Monoclonal Antibodies (mABs), vol. 4, No. 2, Mar. 1, 2012, pp. 182-197.
[cited by applicant]
Kulmanov et al., Bioinformatics, vol. 34(4), 2018, pp. 660-668.
[cited by applicant]
Lazar et al., Mol. Cell., vol. 8, 1988, pp. 1247-1252.
[cited by applicant]
Lorenzen et al., “The Structure of the Interleukin-15 Receptor and Its Implications for Ligand Binding”, Journal of Biological Chemistry, vol. 281, No. 10, Apr. 2006, pp. 6642-6647.
[cited by applicant]
McKeague et al., “Challenges and Opportunities for Small Molecule Aptamer Development”, Journal of Nucleic Acids, vol. 2012, Article 748913, Oct. 2012, 20 pages.
[cited by applicant]
Miosge, Proc Nat'l Acad Sci USA, 112(37), Sep. 15, 2015, pp. E5189-E5198.
[cited by applicant]
Application No. PCT/US2018/021301, International Search Report and Written Opinion, dated Jun. 19, 2018, 12 pages.
[cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proceeding of the National Academy of Sciences (PNAS), vol. 79, No. 6, Mar. 1, 1982, pp. 1979-1983.
[cited by applicant]
Skolnick et al., Trends Biotechnol., 18(1), Jan. 2000, pp. 34-39.
[cited by applicant]
Terai et al., “Human interleukin 10 receptor 1/lgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential,” Cancer Immunol Immunother, 2009, vol. 58, No. 8, pp. 1307-1317.
[cited by applicant]
Vajdos et al., J Mol Biol, 320(2), Jul. 5, 2002, pp. 415-428.
[cited by applicant]
Warzocha et al., “Antisense Strategy: Biological Utility and Prospects in the Treatment of Hematological Malignancies”, Leukemia & Lymphoma, vol. 24, Issue 3-4, 1997, pp. 267-281.
[cited by applicant]
Zou et al., “Structure-Function Analysis of the p35 Subunit of Mouse Interleukin 12”, The Journal of Biological Chemistry, vol. 270, No. 11, Mar. 17, 1995, pp. 5864-5871.
[cited by applicant]